Biomerica to Launch inFoods® IBS Pilot with 1,100-Member Physician Group in June 2024

Irritable Bowel Syndrome (IBS) is a condition that affects 10 to 15% of the global population, leading to significant healthcare costs estimated at $21 billion annually. Recognized as the seventh most common diagnosis among physicians, IBS presents a considerable healthcare challenge. Biomerica, Inc., a company specializing in advanced medical diagnostics and therapeutics, has developed a groundbreaking product called inFoods IBS, which identifies foods that trigger IBS symptoms, thereby offering a novel approach to managing the condition.

Biomerica announced the initiation of a pilot program for its inFoods IBS product with a substantial 1,100-member physician group, set to commence in June 2024. This pilot aims to revolutionize the management of IBS by identifying patient-specific dietary triggers. The inFoods IBS technology has demonstrated significant success in alleviating symptoms for the majority of patients involved in a comprehensive clinical study.

IBS incurs substantial direct medical costs and productivity losses, highlighting the need for innovative treatment solutions. Current treatments often fall short in effectiveness, underscoring the importance of advancements such as inFoods IBS. The product has undergone rigorous testing in a prospective, double-blind, placebo-controlled endpoint study at renowned institutions including the Mayo Clinic, Beth Israel Deaconess Medical Center (a Harvard Medical School Teaching Hospital), Houston Methodist Hospital, and the University of Michigan. Results from these studies showed a notable improvement in Abdominal Pain Intensity scores for IBS patients in the treatment diet group compared to the placebo group, with a statistically significant p-value of 0.0246. The majority of patients experienced substantial symptom relief with inFoods IBS.

The positive clinical data of inFoods IBS will be presented at the 2024 Digestive Disease Week (DDW) conference in Washington D.C., an event that serves as a premier international gathering of healthcare professionals specializing in digestive diseases.

Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures, and markets advanced diagnostic and therapeutic products. These products are used in various settings, including at home, in physicians' offices, and in hospital or clinical laboratories. Biomerica's primary focus is on gastrointestinal and inflammatory diseases, and the company has multiple diagnostic and therapeutic products in development aimed at enhancing health outcomes while reducing overall healthcare costs.

The inFoods IBS test is designed to assess a patient's abnormal immunoreactivity to specific foods using a simple finger-stick blood sample. This allows physicians to make targeted, patient-specific dietary recommendations, potentially alleviating IBS symptoms such as pain, bloating, diarrhea, and constipation. Clinical trials conducted at prestigious centers have shown significant improvements in Abdominal Pain Intensity for patients using the inFoods IBS treatment diet compared to those on a placebo diet.

In summary, Biomerica's inFoods IBS product represents a significant advancement in the management of IBS, addressing a critical need for effective treatment solutions. The upcoming pilot program and the presentation of positive clinical data at a major medical conference underscore the growing recognition and therapeutic utility of this innovative technology.